Physician profile
Michael E Hillman
NPI 1740867753
$362.59
in general payments reported to CMS, 2019-2025
12 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $164 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $116.39 | 2024-2025 | |
| Dexcom, INC. | $41.10 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $33.65 | 2024 | Wegovy |
| Daiichi Sankyo INC. | $28.64 | 2025 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $26.21 | 2024 | Rexulti |
| Corcept Therapeutics | $19.52 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $19.28 | 2025 | Spravato |
| Acadia Pharmaceuticals INC | $18.79 | 2024 | Daybue |
| Sumitomo Pharma America, INC. | $18.76 | 2025 | Gemtesa |
| Edwards Lifesciences Corporation | $16.08 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Axsome Therapeutics, INC. | $16.06 | 2025 | Symbravo |
| Phathom Pharmaceuticals, INC. | $8.11 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.